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It is important to note that Hoste et 
al. (2011) have not proposed that cas-
pase-14 is the only protease that cleaves 
filaggrin. Rather, their report shows that, 
in the absence of caspase-14, other 
enzymes can initiate proteolysis of filag-
grin. In addition, proteases such as cal-
pain 1 and bleomycin hydrolase (Kamata 
et al., 2009) are required to complete 
the degradation of filaggrin. Therefore, 
to understand the regulation of filaggrin 
degradation, it is necessary to determine 
the interplay of caspase-14 with these 
other proteases as well as the order in 
which the proteolytic cuts occur.
concluding remarks
New evidence demonstrates that not 
only mutations in the filaggrin gene but 
also alterations in filaggrin processing 
may result in skin barrier defects and 
that caspase-14 takes part in this pro-
cess. Hoste et al. (2011) provide a basis 
for improving strategies to diagnose 
filaggrin-associated skin disorders and to 
modulate caspase-14-dependent barrier 
function of the stratum corneum.
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Demonstration of Epitope Spreading 
in Bullous Pemphigoid: Results of a 
Prospective Multicenter Study
Takashi Hashimoto1,2, Daisuke Tsuruta1,2, Teruki Dainichi1,2, Takahiro 
Hamada1,2, Minao Furumura1,2 and Norito Ishii1,2
Di Zenzo and colleagues have undertaken a multicenter prospective study 
to clarify the epitope profile for IgG anti-BP180 and BP230 antibodies in 35 
patients with bullous pemphigoid (BP). Both intra- and intermolecular epitope 
spreading events were observed, in which epitopes shifted exclusively from 
extracellular to intracellular domains. The presence of IgG antibodies to the 
BP180 C-terminal domain and BP230, in addition to the BP180-NC16A domain, 
correlated with disease severity and activity, suggesting specific pathogenic rel-
evance for anti-BP230 antibodies. Epitope spreading was found in both T- and 
B-cell recognition. IgA anti LAD-1 antibodies are frequently found in patients 
with BP; these antibodies appear to follow the development of IgG antibodies 
to BP180 and BP230 by epitope spreading. These observations provide direction 
for future studies of the pathogenesis of and treatments for BP.
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epitope spreading plays an  
important role in the development  
of autoimmune diseases
Various autoimmune diseases develop 
and progress via epitope spreading (ES). 
In ES, inflammation induced by auto-
immunity to an initial epitope damages 
target tissue, which subsequently induc-
es antibodies to secondary epitopes on 
the same or different antigens (Chan 
et al., 1998). Intra- or intermolecular 
ES is not simply an epiphenomenon, 
because it is important for the develop-
ment of each disease.
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Previous studies in bullous 
pemphigoid (BP), using both human 
materials and mouse models, have 
clarified the progress and relevance 
of ES (Di Zenzo et al., 2008, 2010). 
A retrospective study of BP sera by 
enzyme-linked immunosorbent assays 
(ELISA) that used recombinant pro-
teins of BP180 and BP230 suggested 
the occurrence of ES in patients with 
BP (Yoshida et al., 2006). However, 
the precise development and progress 
of ES and its correlation to BP disease 
activity have not been elucidated.
Di Zenzo et al. (2011, this issue) 
performed a multicenter prospective 
epitope profile study of IgG antibodies 
to both BP180 and BP230 during the 
clinical course of 35 patients with 
BP. ES occurred in about half of the 
patients. Intramolecular ES in BP180 
occurred first in the extracellular 
domain and then spread to the intra-
cellular domain. Intermolecular ES 
also occurred and spread from BP180 
to BP230. Finally, reactivity, both with 
extracellular BP180 epitopes and with 
intracellular BP230 epitopes, corre-
lated with disease severity and activity, 
suggesting pathogenic significance for 
the anti-BP230 autoantibodies.
eS occurred in patients with BP
Over a 12-month period, ES was found 
in 17 (49%) of 35 patients with BP, 
whereas 18 (51%) showed no epi-
tope shifts. All 17 patients showing ES 
reacted with BP180 epitopes, and 12 
reacted with BP230 epitopes at the 
time of diagnosis. Twenty-four differ-
ent ES events were observed, and ES 
from extracellular BP180 epitopes to 
intracellular epitopes of BP180 and 
BP230 occurred most frequently. ES 
also occurred before the development 
of overt clinical manifestations of BP.
eS always spread from extracellular to 
intracellular domains
Three BP patients showed ES from 
extracellular BP180 epitopes to 
intracellular epitopes of BP180 and 
BP230, whereas the opposite was not 
observed. In addition, three patients 
showed intermolecular ES from BP180 
epitopes to BP230 epitopes, whereas 
the opposite did not occur. This single 
direction of ES events should provide 
important insights into the mechanism 
of ES.
this study indicated clinical significance 
of eS events in BP
ES events occurred most frequently in 
the first 3 months after BP diagnosis, 
suggesting that ES is an early event in 
the course of the disease. Accordingly, 
ES was observed rarely during relapses 
of the disease. Perhaps immunosup-
pressive therapy impairs T- and B-cell 
activation, reducing subsequent ES 
events.
Severity and activity of disease were 
correlated with reactivity with both the 
NC16A and the C-terminal domains 
of BP180, but not with the N-terminal 
intracellular domain. Notably, two 
patients with active disease showed 
exclusive reactivity with the BP180 
C-terminal domain. These results indi-
cate that reactivity with the C-terminal 
domain of BP180 is pathogenic not 
only in mucous membrane pemphi-
goid but also in BP.
Importantly, ES was clearly related 
to disease severity and activity at the 
time of diagnosis. It is interesting that 
reactivity with epitopes occurred later 
via ES decreased rapidly. IgG reactivity 
with BP180 extracellular domains and 
with BP230 intracellular domains was 
clearly related to disease severity and 
activity, whereas reactivity with BP180 
intracellular domains was not. These 
results suggest that not only antibod-
ies to BP180 extracellular domains but 
also antibodies to BP230 are patho-
genic, whereas reactivity with BP180 
intracellular domains is an epiphe-
nomenon.
anti-BP230 autoantibodies were 
suggested to be pathogenic
Three patients without BP180-NC16A 
reactivity nonetheless reacted with 
other BP180 and BP230 epitopes. As 
mentioned above, IgG reactivity with 
BP230 was clearly related to disease 
severity and activity, suggesting that 
anti-BP230 antibodies are pathogenic. 
Although reactivity with BP230 has 
generally been considered a non-
pathogenic epiphenomenon, previous 
evidence suggests a pathogenic role 
for anti-BP230 antibodies. Anti-BP230 
antibodies induced skin lesions in a 
mouse model, and BP230 titers by 
immunoblotting and ELISA correlated 
with disease activity (Hamada et al., 
2001; Yoshida et al., 2006). Recently, 
sera we collected from 35 patients with 
active BP showed only anti-BP230 
antibodies by ELISA, reacted only with 
intracellular sites of hemidesmosomes 
by immunoelectron microscopy, and 
showed a unique ES profile (Fujihara 
et al., 2011). This combination of evi-
dence suggests pathogenic signifi-
cance for BP230 antibodies in BP and 
would thus indicate that autoantibod-
ies bind to intracellular antigens by 
unknown mechanisms.
nonpathogenic Iga anti-LaD-1 
antibodies were found frequently in BP
Di Zenzo et al. (2011) detected IgA 
reactivity with LAD-1 in 11 of their 
35 patients. This result complements 
that of our study, in which a signifi-
cant number of BP sera possessed IgA 
antibodies reactive with recombinant 
protein of LAD-1 by ELISA (Csorba et 
al., 2011). In four patients in the pres-
ent study, IgG reactivity with BP180 
and BP230 spread to IgA reactivity 
with LAD-1. However, because IgA 
anti-LAD-1 antibodies showed no 
association with disease severity and 
activity, disease duration, mucosal 
involvement, or ES, they were consid-
ered to have a limited pathogenic role. 
Clinical Implications
•  Intra- and intermolecular epitope spreading (ES) is observed in bullous 
pemphigoid (BP); epitopes shift from extracellular to intracellular 
domains.
•  The presence of IgG antibodies to the BP180 C-terminal domain and 
BP230, in addition to the BP180-NC16A domain, correlates with disease 
severity and activity. ES is found for both T- and B-cell recognition in BP.
•  Analysis of ES may provide clues for developing novel therapies.
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Nevertheless, because this finding may 
provide insight into development of 
pathogenic IgA anti-LAD-1 antibod-
ies in linear IgA bullous dermatosis, 
further experiments should explore 
the mechanisms of class switching 
between IgG and IgA.
eS also occurred in t-cell recognition
ES in T-cell reactivity was examined in 
nine of the patients with BP, and a pro-
liferative T-cell response to BP180 and/
or BP230 was observed in five. Two of 
these five patients showed ES events in 
T-cell recognition. One showed a shift 
from the extracellular BP180 domain 
to the BP230 C-terminal domain, 
and another showed a shift from the 
BP180-NC16A domain to the BP180 
C-terminal domain. In general, auto-
reactive B and T cells showed similar 
epitope profiles throughout the course 
of the disease.
Perspectives
In this report of their prospective study, 
Di Zenzo et al. reveal many novel 
and interesting results. In future stud-
ies, the pathogenic role in BP should 
be confirmed for IgG antibodies to 
the BP230 and the BP180 C-terminal 
domain, as well as for IgA anti-LAD-1 
antibodies. Novel ES mechanisms may 
be discovered in the production of 
pathogenic IgG anti-BP230 antibodies 
and IgA anti-LAD-1 antibodies.
Di Zenzo and co-workers’ results 
also give us insight into potential new 
treatments, including the use of decoy 
peptides, tolerance-inducing peptides, 
and antigen-specific immunoabsorp-
tion. In particular, the rapid decrease of 
autoantibodies against ES-induced late 
epitopes should yield clues for pursu-
ing novel therapeutic approaches.
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